Navigation Links
Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
Date:3/20/2013

WILMINGTON, Del., March 20, 2013 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the leading biobutanol technology company, announced today it would appeal the Court's claim construction and decisions on certain motions before the Court in Butamax's litigation against Gevo.

Paul Beckwith , Butamax Chief Executive Officer, stated, "Butamax has decided to appeal this case immediately.  Butamax strongly disagrees with the Court's claim construction.  We do not believe it is consistent with either the patent, rules for patent claim construction or statements made by the Federal Circuit.  We have therefore decided to appeal immediately to resolve this matter before going to trial.  We are confident the Federal Circuit will determine this matter in our favor."

The Court made no overall determination on literal infringement and denied Gevo's motions of invalidity on all but two of 37 patent claims being asserted by Butamax against Gevo.  However, despite previous statements from the Federal Circuit, the Court chose a very narrow claim construction for the KARI enzyme element of the claims.  This narrow interpretation, in Butamax's view, is in error as a matter of law and therefore Butamax is taking this claim construction immediately back to the Federal Circuit for appeal.

Beckwith continues, "This is still an early stage in what is likely to be a long and complicated litigation, involving many patents that will take several years for the courts to resolve.   Butamax is currently enforcing six other patents against Gevo and will vigorously continue to do so while this case is appealed."

Butamax remains strongly committed to near term commercialization of its biobutanol technology.  Butamax will continue its strategy of bringing advanced biofuels to the consumer and providing a real solution to the blendwall.

About Butamax 

Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:  
Mark Buse  202-679-5576 
Mark.Buse@butamax.com

 


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
3. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
4. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
5. USPTO Grants Butamax a Further KARI Enzyme Patent
6. Gevo Doesnt Infringe Butamaxs 017 Patent; Gevo was First to Invent Enzyme in 017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
7. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
10. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
11. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way ... beautiful technology experience. All three tenets were on display at the 2nd Annual DrugDev ... over 40 sponsor, CRO and site organizations to discuss innovation and the future of ...
(Date:12/2/2016)... , Dec. 1, 2016   SurePure, Inc. ... announced today that the Company has concluded an agreement ... right for a 90-day period to acquire units of ... of approximately USD 3.7 million.  Concurrently ... with Tamarack under which Tamarack will seek regulatory approvals ...
(Date:11/30/2016)... CLEVELAND , Nov. 30, 2016  GenomOncology today announced ... Vice President of Medical Affairs.  Dr. Coleman ... enhancing the company,s proprietary knowledge-enabled platform. The GenomOncology software suite ... of genetic sequencing data and clinical decision support, from quality ... , ...
(Date:11/30/2016)... , Nov. 30, 2016  The Allen Institute ... Collection: the first publicly available collection of gene ... that target key cellular structures with unprecedented clarity. ... these powerful tools are a crucial first step ... better understand what makes human cells healthy and ...
Breaking Biology Technology:
(Date:11/30/2016)... Poland , Nov. 30, 2016 Not many of us realize that ... aspects of recovery so we need to do it well. Inadequate sleep levels have ... high blood pressure, stroke, diabetes, and even cancer. Maybe now is the ... present that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
Breaking Biology News(10 mins):